548 research outputs found
Renal disaster relief in Europe: the experience at L'Aquila, Italy, in April 2009
On 6 April 2009, an earthquake struck the city of L'Aquila and the surrounding Abruzzo mountains. The disaster left 66 000 people homeless, while 1500 were wounded and 298 died. Although Europe as a whole is not so often affected by massive earthquakes, Italy is an exception with 12 earthquakes with an intensity >6.0 on the Richter scale during the last 100 years. This article offers preliminary information on the L'Aquila earthquake. For the time being, nine AKI patients who needed dialysis treatment are known. In all of them, kidney function recovered. This positive result can be attributed to the efficient and intensive rescue efforts coupled to the availability of disaster plans that had been developed in advance. This article stresses the importance of (i) advance planning of disaster rescue; (ii) the inclusion in these plans of approaches for kidney problems and their complications; (iii) the formulation of recommendations supporting (para-) medical professionals in their preventive, therapeutic and logistic approach to massive incidences of crush
A novel formulation of glucoseâsparing peritoneal dialysis solutions with lâcarnitine improves biocompatibility on human mesothelial cells
The main reason why peritoneal dialysis (PD) still has limited use in the management of patients with endâstage renal disease (ESRD) lies in the fact that the currently used glucoseâbased PD solutions are not completely biocompatible and determine, over time, the degeneration of the peritoneal membrane (PM) and consequent loss of ultrafiltration (UF). Here we evaluated the biocompatibility of a novel formulation of dialytic solutions, in which a substantial amount of glucose is replaced by two osmometabolic agents, xylitol and Lâcarnitine. The effect of this novel formulation on cell viability, the integrity of the mesothelial barrier and secretion of proâinflammatory cytokines was evaluated on human mesothelial cells grown on cell culture inserts and exposed to the PD solution only at the apical side, mimicking the condition of a PD dwell. The results were compared to those obtained after exposure to a panel of dialytic solutions commonly used in clinical practice. We report here compelling evidence that this novel formulation shows better performance in terms of higher cell viability, better preservation of the integrity of the mesothelial layer and reduced release of proâinflammatory cytokines. This new formulation could represent a step forward towards obtaining PD solutions with high biocompatibility
The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis.
Peritoneal dialysis (PD) is a viable but under-prescribed treatment for uremic patients. Concerns about its use include the bio-incompatibility of PD fluids, due to their potential for altering the functional and anatomical integrity of the peritoneal membrane. Many of these effects are thought to be due to the high glucose content of these solutions, with attendant issues of products generated during heat treatment of glucose-containing solutions. Moreover, excessive intraperitoneal absorption of glucose from the dialysate has many potential systemic metabolic effects. This article reviews the efforts to develop alternative PD solutions that obviate some of these side effects, through the replacement of part of their glucose content with other osmolytes which are at least as efficient in removing fluids as glucose, but less impactful on patient metabolism. In particular, we will summarize clinical studies on the use of alternative osmotic ingredients that are commercially available (icodextrin and amino acids) and preclinical studies on alternative solutions under development (taurine, polyglycerol, carnitine and xylitol). In addition to the expected benefit of a glucose-sparing approach, we describe an 'osmo-metabolic' approach in formulating novel PD solutions, in which there is the possibility of exploiting the pharmaco-metabolic properties of some of the osmolytes to attenuate the systemic side effects due to glucose. This approach has the potential to ameliorate pre-existing co-morbidities, including insulin resistance and type-2 diabetes, which have a high prevalence in the dialysis population, including in PD patients
Impact of the rs1024611 polymorphism of ccl2 on the pathophysiology and outcome of primary myelofibrosis
Single nucleotide polymorphisms (SNPs) can modify the individual pro-inflammatory background and may therefore have relevant implications in the MPN setting, typified by aberrant cytokine production. In a cohort of 773 primary myelofibrosis (PMF), we determined the contribution of the rs1024611 SNP of CCL2âone of the most potent immunomodulatory chemokinesâto the clinical and biological characteristics of the disease, demonstrating that male subjects carrying the homozygous genotype G/G had an increased risk of PMF and that, among PMF patients, the G/G genotype is an independent prognostic factor for reduced overall survival. Functional characterization of the SNP and the CCL2-CCR2 axis in PMF showed that i) homozygous PMF cells are the highest chemokine producers as compared to the other genotypes; ii) PMF CD34+ cells are a selective target of CCL2, since they uniquely express CCR2 (CCL2 receptor); iii) activation of the CCL2-CCR2 axis boosts pro-survival signals induced by driver mutations via Akt phosphorylation; iv) ruxolitinib effectively counteracts CCL2 production and down-regulates CCR2 expression in PMF cells. In conclusion, the identification of the role of the CCL2/CCR2 chemokine system in PMF adds a novel element to the pathophysiological picture of the disease, with clinical and therapeutic implications
Predialysis and dialysis therapies differently affect nitric oxide synthetic pathway in red blood cells from uremic patients: Focus on peritoneal dialysis
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia
Polyphosphoinositides (PPIns) and their modulating enzymes are involved in regulating many important cellular functions including proliferation, differentiation or gene expression, and their deregulation is involved in human diseases such as metabolic syndromes, neurodegenerative disorders and cancer, including Acute Myeloid Leukemia (AML). Given that PPIns regulating enzymes are highly druggable targets, several studies have recently highlighted the potential of targeting them in AML. For instance many inhibitors targeting the PI3K pathway are in various stages of clinical development and more recently other novel enzymes such as PIP4K2A have been implicated as AML targets. PPIns have distinct subcellular organelle profiles, in part driven by the specific localisation of enzymes that metabolise them. In particular, in the nucleus, PPIns are regulated in response to various extracellular and intracellular pathways and interact with specific nuclear proteins to control epigenetic cell state. While AML does not normally manifest with as many mutations as other cancers, it does appear in large part to be a disease of dysregulation of epigenetic signalling and many novel therapeutics are aimed at reprogramming AML cells toward a differentiated cell state or to one that is responsive to alternative successful but limited AML therapies such as ATRA. Here, we propose that by combining bioinformatic analysis with inhibition of PPIns pathways, especially within the nucleus, we might discover new combination therapies aimed at reprogramming transcriptional output to attenuate uncontrolled AML cell growth. Furthermore, we outline how different part of a PPIns signalling unit might be targeted to control selective outputs that might engender more specific and therefore less toxic inhibitory outcomes
Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results
n/
Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients
- âŠ